A detailed history of Ikarian Capital, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 100,000 shares of ETNB stock, worth $949,000. This represents 0.1% of its overall portfolio holdings.

Number of Shares
100,000
Holding current value
$949,000
% of portfolio
0.1%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$6.18 - $11.66 $618,000 - $1.17 Million
100,000 New
100,000 $727,000
Q4 2022

Feb 14, 2023

BUY
$5.52 - $12.73 $1.4 Million - $3.23 Million
254,000 Added 127.0%
454,000 $5.78 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $604,000 - $1.4 Million
200,000 New
200,000 $1.16 Million
Q1 2021

May 17, 2021

SELL
$20.22 - $26.73 $663,195 - $876,717
-32,799 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$23.16 - $28.08 $7.12 Million - $8.63 Million
-307,437 Reduced 90.36%
32,799 $799,000
Q3 2020

Nov 16, 2020

BUY
$24.34 - $38.82 $8.28 Million - $13.2 Million
340,236 New
340,236 $8.73 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $441M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.